Combining MDMA and Cannabis Produced Lasting Immune System Changes in Regular Users | Research

The takeaway

People who used both MDMA and cannabis showed sustained decreases in immune cells and increased infection rates over a year, with cannabis-only users showing intermediate effects.

Read this if you use cannabis in combination with other substances and want to understand potential immune system effects.

Immune changes persisted over 12 months in MDMA+cannabis users

What the researchers found

Researchers followed three groups over one year with assessments at baseline, 6 months, and 12 months: 37 people who used both MDMA and cannabis, 23 cannabis-only users, and 34 non-using controls.

The MDMA-cannabis group showed significantly decreased IL-2 (a pro-immune cytokine) and increased TGF-beta1 (an anti-inflammatory marker), along with reduced total lymphocytes, CD4 cells, and natural killer cells. The cannabis-only group showed intermediate changes between the MDMA-cannabis users and controls.

These immune alterations persisted across all three time points, suggesting they were sustained rather than acute effects. Regular MDMA-cannabis users had significantly more mild infections (colds, respiratory issues) than occasional users or controls.

No difference was found between regular and occasional MDMA users for the immune markers, though infection rates were higher in regular users.

Why it matters

Most drug interaction research focuses on acute effects. This study showed that combined MDMA and cannabis use produced immune system changes that persisted over at least a year and translated into measurable health consequences (more infections).

The numbers in context

37 MDMA+cannabis users, 23 cannabis-only users, 34 controls. Decreased: IL-2, total lymphocytes, CD4 cells, NK cells. Increased: TGF-beta1. Higher mild infection rate in regular MDMA+cannabis users. Immune changes sustained over 12 months.

How the study worked

Longitudinal prospective study with three cross-sectional evaluations at baseline, 6 months, and 1 year. Cell-mediated immune function was assessed through cytokine panels and immune cell counts. Infection history was documented through self-report and medical records.

What this study cannot tell us

Polydrug users often use additional substances not accounted for in this study. Self-reported drug use may be inaccurate. The observational design cannot confirm that drug use caused the immune changes rather than pre-existing differences. Sample sizes were relatively small.

How to read the evidence

This is a longitudinal cohort study with three time points and appropriate control groups, providing moderate evidence though limited by small sample sizes and observational design.

When this study was published

Published in 2007. Research on cannabis-drug interactions and immune effects has continued, though MDMA-cannabis immune interaction studies remain limited.

The bigger picture

This study raised important questions about the cumulative immune effects of polydrug use. While cannabis alone showed intermediate immune effects, the combination with MDMA produced more pronounced and sustained immune suppression, a pattern relevant given the common co-use of these substances in recreational settings.

Questions still open

Do the immune changes reverse with sustained abstinence? Does cannabis alone at higher use levels produce similar immune suppression? Are the increased infections clinically significant or limited to minor illnesses?

Common questions

Does cannabis alone affect the immune system?

In this study, cannabis-only users showed immune changes that fell between the MDMA+cannabis group and controls, suggesting cannabis alone may have some immune effects, though less pronounced than the combination.

What kinds of infections increased?

The study documented mild infections such as colds and respiratory infections. Serious or life-threatening infections were not reported.

Read the original research

Combined immunomodulating properties of 3,4-methylenedioxymethamphetamine (MDMA) and cannabis in humans.

Addiction (Abingdon, England), 102(6), 931-6

View on PubMed ↗

Citation

Pacifici, Roberta; Zuccaro, Piergiorgio; Farré, Magí; Poudevida, Sandra; Abanades, Sergio; Pichini, Simona; Langohr, Klaus; Segura, Jordi; de la Torre, Rafael. (2007). Combined immunomodulating properties of 3,4-methylenedioxymethamphetamine (MDMA) and cannabis in humans.. Addiction (Abingdon, England), 102(6), 931-6.